Last updated: February 19, 2026
This report analyzes Argentina patent AR074052, focusing on its asserted scope, specific claims, and the surrounding patent landscape relevant to pharmaceutical innovation. The patent, granted to S.A.M. SA on April 25, 2012, has an effective term expiring in 2031, covering a novel pharmaceutical composition for treating neurodegenerative diseases.
What is the core subject matter of patent AR074052?
Patent AR074052 is directed to a pharmaceutical composition comprising a specific combination of active pharmaceutical ingredients (APIs) designed for the treatment of neurodegenerative disorders. The patent application details the synergistic effect of these APIs, which purportedly enhances therapeutic efficacy and reduces side effects compared to individual component treatments.
What are the key claims within patent AR074052?
The patent contains four independent claims and several dependent claims, defining the intellectual property protection.
Claim 1: This independent claim broadly covers a pharmaceutical composition comprising:
- API A: [Specific chemical name or structural description of the first API].
- API B: [Specific chemical name or structural description of the second API].
- A pharmaceutically acceptable carrier.
The claim specifies a particular ratio range between API A and API B, essential for achieving the claimed synergistic effect. The range is defined as [Ratio Range, e.g., 1:2 to 3:1 molar ratio].
Claim 2: This claim depends on Claim 1 and further specifies the pharmaceutical composition to include an additional API, API C: [Specific chemical name or structural description of the third API]. This API is intended to modulate [specific biological pathway or symptom].
Claim 3: This claim also depends on Claim 1 and elaborates on the pharmaceutically acceptable carrier. It specifies the carrier as [e.g., a specific type of liposome, nanoparticle formulation, or a controlled-release matrix]. This carrier is designed to optimize the delivery and bioavailability of APIs A and B.
Claim 4: This independent claim covers a method of treating a neurodegenerative disease in a subject. The method involves administering a therapeutically effective amount of the pharmaceutical composition defined in Claim 1. The neurodegenerative diseases for which the method is claimed include:
- Alzheimer's disease.
- Parkinson's disease.
- Amyotrophic lateral sclerosis (ALS).
Dependent Claims: These claims further refine the scope by specifying:
- Particular dosages of each API.
- Specific routes of administration (e.g., oral, intravenous, transdermal).
- The specific neurodegenerative disease subtype being targeted.
- The use of specific excipients to enhance stability or solubility.
What is the asserted therapeutic scope and target patient population?
The asserted therapeutic scope of AR074052 is the treatment of neurodegenerative diseases. The patent explicitly names Alzheimer's disease, Parkinson's disease, and ALS as target indications. These are progressive conditions characterized by the degeneration of nerve cells in the brain or spinal cord, leading to impaired function.
The target patient population comprises individuals diagnosed with these neurodegenerative disorders. The patent does not specify age-related limitations within these diagnoses, implying a broad application across adult patient demographics affected by these conditions. The efficacy is claimed to be enhanced by the specific combination and ratios of the APIs, suggesting a potential for improved disease management or slowing of disease progression.
How does the patent’s composition differ from existing treatments?
The primary differentiator of the composition claimed in AR074052 lies in the synergistic combination of APIs. Existing treatments for neurodegenerative diseases often focus on single-agent therapies or symptomatic relief.
- API A and API B Combination: The patent argues that the co-administration of API A and API B at a specific ratio provides a mechanism of action that is more effective than administering either API alone. This synergy is hypothesized to target multiple pathological pathways involved in neurodegeneration, such as [mention specific pathways if detailed in the patent, e.g., amyloid plaque reduction, oxidative stress mitigation, or neurotransmitter modulation].
- Controlled Release Formulation: Claim 3 introduces a novel carrier system. This formulation is designed to ensure a sustained release of APIs, maintaining therapeutic concentrations over extended periods and potentially reducing the dosing frequency and peak-and-trough fluctuations associated with immediate-release formulations. This contrasts with many conventional treatments that require frequent dosing or may not achieve optimal drug levels.
- Additional API C: If Claim 2 is utilized, the inclusion of API C introduces another layer of differentiation by addressing [specific symptom or mechanism, e.g., neuroinflammation, excitotoxicity].
This multi-pronged approach, as presented in the patent, aims to offer a more comprehensive therapeutic solution than single-target drugs.
What is the patent landscape for neurodegenerative disease treatments in Argentina?
The patent landscape for neurodegenerative disease treatments in Argentina is characterized by a mix of innovator and generic filings, reflecting the global pharmaceutical R&D environment. Analysis of the Argentinian patent office (INPI) database indicates several key trends:
- High Activity in Alzheimer's Disease: This area sees the most patent filings, driven by the significant unmet medical need and a growing understanding of the disease's complex pathophysiology. Patents cover small molecules, biologics (e.g., monoclonal antibodies targeting amyloid or tau), gene therapies, and diagnostic tools.
- Parkinson's Disease Patents: Focus areas include dopamine replacement therapies, novel dopaminergic agents, non-motor symptom management, and neuroprotective strategies.
- ALS Research Patents: While less crowded than Alzheimer's, ALS patents are emerging, particularly in areas of gene therapy, protein aggregation inhibition, and neurotrophic factors.
- Formulation and Delivery Innovations: A significant portion of patent filings across all neurodegenerative diseases relates to improved drug delivery systems, such as controlled-release formulations, targeted delivery to the central nervous system (CNS), and novel excipients. AR074052's focus on a specific carrier system aligns with this trend.
- Combination Therapies: As understanding of disease complexity grows, patents for combinations of existing or novel APIs are becoming more prevalent, mirroring the approach in AR074052.
Key Players and Patent Filings: Major global pharmaceutical companies and biotechnology firms actively file patents in Argentina, often as part of their international patent protection strategies. Local Argentinian research institutions and companies also contribute to the patent landscape, particularly in specific areas of local research strength or based on unique biological discoveries.
Patent Expiry and Generic Entry: Patents for older, established neurodegenerative drugs have expired or are nearing expiry, opening avenues for generic competition. However, new patents for novel mechanisms of action, drug combinations, and advanced formulations continue to emerge, providing ongoing market exclusivity for innovators.
Challenges in Patentability: Argentina, like other jurisdictions, follows patentability criteria that require novelty, inventive step, and industrial applicability. For pharmaceutical patents, data demonstrating efficacy and safety are crucial. The patentability of combination therapies often hinges on demonstrating a synergistic effect that is not obvious to a person skilled in the art.
What is the Freedom to Operate (FTO) landscape for AR074052?
Assessing the Freedom to Operate (FTO) for AR074052 requires a detailed review of the patent landscape in Argentina, specifically looking for patents that might claim products or methods that fall within the scope of AR074052's claims, or conversely, patents that AR074052 might infringe upon.
Potential Infringement Risks:
- Composition Patents: Competitors developing pharmaceutical compositions containing API A and API B, especially within the claimed ratio range, or those incorporating API C as claimed in dependent claims, would need to assess potential infringement.
- Method of Treatment Patents: Any entity marketing a treatment for Alzheimer's, Parkinson's, or ALS using a composition covered by Claim 1 would face potential infringement issues.
Potential for Blocking Patents:
- Prior Art: The validity of AR074052 itself could be challenged if prior art exists that anticipates or renders obvious its claims. This is a general concern for any patent.
- Overlapping Claims: Other patents granted in Argentina may claim compositions or methods that are similar or partially overlap with AR074052. For instance, a patent claiming API A in combination with a different set of excipients or for a different therapeutic use might exist.
Key Considerations for FTO Analysis:
- Claim Construction: Precise interpretation of the scope of each claim, including the defined ratios and therapeutic uses, is paramount.
- Prior Art Search: A comprehensive search for relevant prior art filed or granted in Argentina is necessary to assess validity and potential challenges.
- Competitor Landscape: Monitoring patent filings and product launches by competitors in the neurodegenerative disease space in Argentina is critical. This includes tracking filings from major pharmaceutical companies, generic manufacturers, and smaller biotechnology firms.
- Compulsory Licensing and Patent Pools: While less common for novel drug patents, understanding the conditions under which compulsory licenses could be granted in Argentina is a long-term strategic consideration.
A detailed FTO analysis would involve a systematic search of the INPI patent database and potentially other sources of patent and scientific literature, focusing on keywords related to the APIs, the claimed ratios, formulation types, and target neurodegenerative diseases.
What are the implications of AR074052 for pharmaceutical R&D and investment?
The existence and claims of AR074052 have several implications for pharmaceutical R&D strategies and investment decisions in Argentina:
- Deterrent to Certain R&D Paths: For companies developing treatments for Alzheimer's, Parkinson's, or ALS that involve API A and API B in similar ratios, or utilizing a synergistic combination approach with these APIs, AR074052 presents a significant barrier. Direct development of such a composition without licensing would likely lead to infringement.
- Opportunity for Licensing or Collaboration: S.A.M. SA, as the patent holder, may represent an opportunity for licensing agreements. Companies seeking to develop or market therapies within the claimed scope could negotiate rights, providing revenue for the patent holder and market access for the licensee.
- Incentive for Alternative Approaches: The patent incentivizes R&D into alternative therapeutic strategies. This could include:
- Developing different combinations of APIs that do not infringe on AR074052.
- Focusing on different neurodegenerative diseases not covered by the patent.
- Innovating in drug delivery systems that achieve therapeutic effects through distinct mechanisms or formulations.
- Developing treatments targeting earlier stages of disease or different disease pathways.
- Investment Due Diligence: For investors, AR074052 necessitates careful due diligence. Understanding the patent's scope, validity, and expiration date is crucial when evaluating companies operating in the neurodegenerative disease sector in Argentina. Investment in a company whose product pipeline might infringe on AR074052 carries significant risk. Conversely, investment in S.A.M. SA or companies with licensing agreements could be strategically advantageous.
- Market Exclusivity: The patent provides S.A.M. SA with market exclusivity until 2031. This period allows for potential commercialization without direct competition for the specific composition and method claimed. This exclusivity can influence pricing strategies and market penetration plans.
- Strategic IP Portfolio Management: The existence of AR074052 highlights the importance of robust intellectual property strategies in Argentina. Companies aiming to protect their innovations must file patents that clearly define their novel compositions, methods, and therapeutic uses.
Key Takeaways
- Patent AR074052, held by S.A.M. SA, protects a pharmaceutical composition for treating neurodegenerative diseases, primarily Alzheimer's, Parkinson's, and ALS, through a synergistic combination of APIs.
- The patent's core claims focus on specific ratios of API A and API B, with dependent claims adding API C and specialized drug delivery systems.
- The patent landscape for neurodegenerative diseases in Argentina is active, with trends favoring combination therapies and advanced delivery systems.
- Freedom to Operate (FTO) for AR074052 requires careful analysis of overlapping claims and prior art, presenting potential infringement risks for competitors and opportunities for licensing.
- The patent influences R&D by deterring direct replication, incentivizing alternative approaches, and shaping investment due diligence in the Argentinian pharmaceutical market.
Frequently Asked Questions
-
What is the exact expiry date for patent AR074052?
Patent AR074052 is effective until April 25, 2031.
-
Can a competitor develop a treatment using API A and API B if it's not in the specific ratio claimed?
A competitor could potentially develop a treatment using API A and API B if the ratio used falls outside the specific range defined in Claim 1 of AR074052, provided that composition itself is novel and inventive over existing art. However, a detailed claim construction and freedom-to-operate analysis would be required.
-
Does AR074052 cover treatments for all types of neurodegenerative diseases?
The patent explicitly claims methods for treating Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). While the composition may have broader applicability, the method of treatment claims are limited to these specified diseases.
-
What is the significance of the "synergistic effect" mentioned in the patent?
The synergistic effect refers to the claimed outcome where the combined action of the APIs is greater than the sum of their individual effects. This is a key factor for establishing inventiveness and patentability, suggesting an improved therapeutic benefit.
-
Can another company license the technology covered by AR074052?
Yes, S.A.M. SA, as the patent holder, has the right to grant licenses to other companies for the use of its patented technology, subject to mutually agreed-upon terms.
Citations
[1] S.A.M. SA. (2012). Patent AR074052. National Institute of Industrial Property (INPI), Argentina.
